← Back to Clinical Trials
Recruiting NCT07130487

NCT07130487 Project CARE: CAncer Risk Evaluation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07130487
Status Recruiting
Phase
Sponsor Anita Y. Kinney, PhD, RN
Condition Primary Care
Study Type INTERVENTIONAL
Enrollment 210 participants
Start Date 2025-11-19
Primary Completion 2026-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Relational Agent ( RA) Alex

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 210 participants in total. It began in 2025-11-19 with a primary completion date of 2026-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of Project CARE (cancer risk assessment and evaluation) research study is to explore the acceptance and feasibility of a study-initiated proactive outreach and digital care delivery model for conducting hereditary cancer risk assessment in primary care settings and facilitating genetic risk evaluation for patients flagged as high risk. Potential participants will be recruited from Rutgers Health primary care sites (family practice and general internal medicine). EPIC will be used to identify all potential participants and they will be invited to participate in the study. Consented participants will be provided a link via email, and or text message to engage with a Relational Agent (RA, chatbot), through the patient portal for cancer risk assessment and genetic education. Those identified as high risk will be offered genetic counseling and testing. The research questions the study aims to answer are: 1. What percent of patients who completed the RA are identified as high risk? 2. What percent of patients who engaged with the risk assessment were identified as high risk? 3. What percent of high-risk patients had genetic counseling or genetic testing within 4 months of completing the risk assessment?

Eligibility Criteria

Inclusion Criteria 1. Age 18 to 70 years 2. Able to read and speak English 3. Have an email address or mobile phone number in EPIC and/or are enrolled in MyChart 4. Receiving health care in Family Medicine or General Internal Medicine at Rutgers Health within the past 2 years 5. Have not opted out of receiving research-related communications 6. Have internet access (via smartphone, tablet, or computer) Exclusion Criteria 1. Dementia (e.g., Alzheimer's disease) as indicated in EPIC 2. Unable to access the Internet (via smartphone, tablet, or computer) 3. Previous germline genetic testing for hereditary cancer risk 4. Opted out of research participation in EPIC 5. Have a personal history of cancer

Contact & Investigator

Central Contact

Julie Chapman-Greene, PhD, MPH

✉ chapmaje@cinj.rutgers.edu

📞 732-865-3375

Principal Investigator

Anita Y Kinney, PhD, RN

PRINCIPAL INVESTIGATOR

Rutgers, The State University of New Jersey

Frequently Asked Questions

Who can join the NCT07130487 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Primary Care. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07130487 currently recruiting?

Yes, NCT07130487 is actively recruiting participants. Contact the research team at chapmaje@cinj.rutgers.edu for enrollment information.

Where is the NCT07130487 trial being conducted?

This trial is being conducted at New Brunswick, United States.

Who is sponsoring the NCT07130487 clinical trial?

NCT07130487 is sponsored by Anita Y. Kinney, PhD, RN. The principal investigator is Anita Y Kinney, PhD, RN at Rutgers, The State University of New Jersey. The trial plans to enroll 210 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology